Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy

Anuurad Erdembileg, Asha Thomas-Geevarghese, Sridevi Devaraj, Jeanine Albu, Robert Minolfo, Wafaa M. El-Sadr, Guijing Lu, Wahida Karmally, Lars Berglund

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Increased levels of postprandial triglycerides (TG) and remnant like particles (RLP) are associated with cardiovascular disease. We evaluated whether postprandial lipemia differed in HIV-positive patients with or without different antiretroviral regimens. A standardized high fat load was administered to 28 subjects: 11 HIV-positive subjects receiving protease inhibitors (PI), 10 HIV-positive subjects receiving non-nucleoside reverse transcriptase inhibitors (NNRTI) and 7 HIV-positive subjects not receiving highly active antiretroviral therapy, HAART (Naïve). Baseline TG levels and TG area under the curve (AUC) did not differ among the three groups. The postprandial TG concentration curves were similar in the NNRTI and Naïve groups, peaking at 3-5-h. Baseline RLP cholesterol was higher in the NNRTI group compared to other two groups (P = 0.035). Both HAART groups (NNRTI and PI) had higher postprandial RLP cholesterol AUC than the Naïve group (P = 0.024, ANOVA). In conclusion, during HIV conditions, HAART resulted in a pro-atherogenic pattern with accumulation of remnant lipoproteins.

Original languageEnglish (US)
Pages (from-to)192-197
Number of pages6
Issue number1
StatePublished - May 2008


  • Antiretroviral therapy
  • HIV
  • Non-nucleoside reverse transcriptase inhibitor (NNRTI)
  • Postprandial lipemia
  • Protease inhibitors (PI)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy'. Together they form a unique fingerprint.

Cite this